Liposome Patents (Class 424/9.321)
  • Patent number: 11116854
    Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: September 14, 2021
    Assignee: Texas Children's Hospital
    Inventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
  • Patent number: 10961199
    Abstract: The present invention is related to a compound of formula (I) wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C5)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the formula (II) wherein ALK? is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is selected from the group consisting of H and an Effector moiety; or a pharmacologically acceptable salt, solvate or hydrate thereof.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: March 30, 2021
    Assignee: 3B PHARMACEUTICALS GMBH
    Inventors: Frank Osterkamp, Christiane Smerling, Ulrich Reineke, Christian Haase, Jan Ungewiß
  • Patent number: 9532950
    Abstract: The present invention provides a liposome having excellent lung migration ability that had not existed hitherto, by including GALA or Chol-GALA in the liposome. Furthermore, by using the liposome, a pulmonary delivery carrier having a stronger knockdown effect of siRNA when compared to existing carriers is provided.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: January 3, 2017
    Assignees: National University Corporation Hokkaido University, Taiho Pharmaceutical Co., Ltd.
    Inventors: Kenji Kusumoto, Hideyoshi Harashima, Hidetaka Akita, Hiroto Hatakeyama, Taichi Ishitsuka
  • Patent number: 9408890
    Abstract: This disclosure provides compositions, kits, and methods useful for treating or preventing viral and bacterial infection and reducing or preventing the effects of toxins. The methods comprise administering to a subject an effective amount of a liposomal composition.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: August 9, 2016
    Assignees: The Charles Stark Draper Laboratory, Inc., The Massachusetts Institute of Technology, University of California, Santa Barbara (UCSB), University of Massachusetts Medical School
    Inventors: James Comolli, Jose Trevejo, Ram Sasisekharan, Zachary Shriver, Karthik Viswanathan, Deborah Fygenson, Robert Finberg, Jennifer Wang
  • Patent number: 9005582
    Abstract: A medical delivery system that enables the delivery of therapeutic agents to malignant tissue utilizing delivery agents and heating of the delivery agents thereby causing the release of the therapeutic agents within the tumor is disclosed. The therapeutic agents may be chemotherapy agents, radiation therapy agents, and other appropriate materials. The magnetic nanoparticles encapsulated by the therapeutic agents in a biocompatible coating may be delivered to tumor sites utilizing attenuated strains of bacteria that seek and reside at tumor sites. An alternating magnetic field device with a prescribed frequency range may be used to induce heating of the magnetic nanoparticles in the patient thereby melting the coating and releasing the therapeutic agents within the tumor.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: April 14, 2015
    Assignees: University of North Carolina at Greensboro, United Arab Emirates University
    Inventor: Yousef Haik
  • Patent number: 9005583
    Abstract: There is provided a novel chain-end functionalized PEO of formulas (I) to (IV) prepared via living anionic polymerization and chain-end functionalization, as well as a simple method of preparing nano-sized transition metal or metal salt particles using the same, which can be readily stabilized even in an aqueous medium. The water-soluble PEO-based polymers having various functional groups (including a drug group such as vitamin and anti-cancer agent) and the process of preparing nano-sized transition metal or metal salt particles using the same can be advantageously used in the development of new materials for drug delivering system and imaging, e.g., a contrast agent and an anti-cancer agent simultaneously.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: April 14, 2015
    Assignee: Youl Chon Chemical Co., Ltd.
    Inventors: Jungahn Kim, Kwang Ung Kim, Seung Sang Hwang, Soon Man Hong, Soonjong Kwak, Joon Hyeong Park, Ji Hee Kim, Dong Youn Shin, Soon Geun Hwang, Jang Seop Kim, Han Wook Ryu
  • Publication number: 20150064115
    Abstract: Novel liposomal nanoparticle that has been engineered to be particularly useful for the delivery of compounds to cells found in the peripheral nervous system, and to endothelial cells that form the blood brain barrier. These nanoparticles are intended to be useful for the delivery of compounds suitable for therapeutic purposes and imaging contrast agents that may not otherwise gain access to neuronal axons, or glial cells regions of the brain. Particularly advantageous for the purpose of targeting neural cells, endothelial cells of the blood vessels and epithelial cells of the choroid plexus that serve the brain is the inclusion, in the nanoparticles of cholesterol that surprisingly increases the affinity of the nanoparticles for such as Schwann cells, glial cells, and the like. Image contrast agents, such as those suitable for use in MRI techniques may also be delivered to neural cells, including of the peripheral nervous system.
    Type: Application
    Filed: March 6, 2013
    Publication date: March 5, 2015
    Inventors: Ana M. Ashizawa, Lucia Notterpek, Tetsuo Ashizawa
  • Patent number: 8951501
    Abstract: A noninvasive thermometry monitoring system for determining a temperature of tissue to which hyperthermia treatment is administered is disclosed. The monitoring system may incorporate magnetic nanoparticles having known moments such that once exposed to an alternating magnetic field, the magnetic nanoparticles increase in temperature. Imaging systems can disclose the magnetic nanoparticles within a patient. The temperature of the magnetic nanoparticles can be determined by comparing the magnetic nanoparticle with known temperatures for that type of magnetic nanoparticle. The image of the magnetic nanoparticles may be compared with surrounding tissue to determine the temperature of the surrounding tissue that is exposed to hyperthermia treatment.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: February 10, 2015
    Assignees: University of North Carolina at Greensboro, United Arab Emirates University
    Inventor: Yousef Haik
  • Patent number: 8945512
    Abstract: Disclosed are CEST paramagnetic agents comprising a substrate (SH) containing mobile protons bonded to a paramagnetic chelate (SR) containing a metal selected from iron (11) (high-spin configuration), iron (111), cobalt (11), rhodium (11), copper (11), nickel (11), cerium (111), praseodymium (111), neodymium (111), dysprosium (111), erbium (111), terbium (111), holmium (111), thulium (III), ytterbium (III) and europium (111).
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: February 3, 2015
    Assignee: Bracco Imaging SpA
    Inventors: Silvio Aime, Enzo Terreno, Daniela Delli Castelli, Giovanni Battista Giovenzana
  • Patent number: 8871724
    Abstract: The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is X1X2X3X3?X1?- (SEQ ID NO: 1), wherein X1 and X1?- are independently selected from the group of basic amino acids, X2 is a lipophilic amino acid and X3 and X3? are independently selected from the group of uncharged amino acids; and wherein the oligopeptidic compound is further characterized by at least one of the following: (i) the oligopeptidic compound comprises at least one signal sequence; (ii) the PCNA interacting motif is [K/R]-F-[L/I/V]-[L/I/V]-[K/R] (SEQ ID NO: 27). Particularly the therapy may be the treatment of a disorder or condition where it is desirable to inhibit the growth of cells, for example a hyperproliferative disorder, or a treatment which involves cytostatic therapy e.g., myeloablation.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: October 28, 2014
    Assignee: Apim Therapeutics AS
    Inventors: Marit Otterlei, Per Arne Aas, Emadoldin Feyzi
  • Patent number: 8784778
    Abstract: The present invention relates to a method for the in vivo, ex vivo, or in vitro determination of physical or chemical parameters of diagnostic interest by use of a slow tumbling paramagnetic agent that is responsive to changes of said physical or chemical parameter through changes in the R2p/R1p ratio allowing the determination of the said parameter in a manner that is independent on the actual agent concentration.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: July 22, 2014
    Assignee: Bracco Imaging S.p.A.
    Inventors: Silvio Aime, Enzo Terreno
  • Publication number: 20140186268
    Abstract: The present invention relates to methods for producing oxide ferrimagnetics with spinel structure and iron oxide nanoparticles by soft mechanochemical synthesis using inorganic salt hydrates, oxide ferrimagnetics with spinel structure and iron oxide nanoparticles of ultra-small size and high specific surface area obtainable by the methods, biocompatible aqueous colloidal systems comprising oxide ferrimagnetics with spinel structure and iron oxide nanoparticles, carriers comprising oxide ferrimagnetics with spinel structure and iron oxide nanoparticles, and uses thereof in medicine.
    Type: Application
    Filed: February 4, 2014
    Publication date: July 3, 2014
    Applicants: Jozef Stefan Institute, Institute of Strength Physics and Materials Science of Siberian Branch Russian Academy of Scie
    Inventors: Olga VASILJEVA, Volya I. ITIN, Sergey G. PSAKHIE, Georgy A. MIKHAYLOV, Mojca Urska MIKAC, Boris TURK, Anna A. MAGAEVA, Evgeniy P. NAIDEN, Olga G. TEREKHOVA
  • Publication number: 20140178296
    Abstract: The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as well as methods of imaging various tissues. The liposome complexes are useful for encapsulation of imaging agents, for example, for use in magnetic resonance imaging. The specificity of the delivery system is derived from the targeting antibodies or antibody fragments.
    Type: Application
    Filed: December 6, 2013
    Publication date: June 26, 2014
    Applicant: Georgetown University
    Inventors: Esther H. CHANG, Kathleen F. Pirollo
  • Publication number: 20140161733
    Abstract: A composition comprising: a liposome having a bilayer structure, a gadofullerene having a high relaxivity, and an amphiphilic receptor ligand. In the composition, the gadofullerene is embedded in the bilayer structure of the liposome. In addition, a method for detecting atherosclerotic plaque in an animal using the composition is described.
    Type: Application
    Filed: March 29, 2012
    Publication date: June 12, 2014
    Applicant: LUNA INNOVATIONS INCORPORATED
    Inventors: Zhiguo Zhou, Robert P. Lenk, Christopher L. Kepley
  • Publication number: 20140086846
    Abstract: A contrast agent composition and a method of diagnostic imaging are provided. The composition comprises a pharmaceutically acceptable carrier and a metal-complex comprising a ligand having structure (XXX): wherein R1, R2, R3, R7, R8, R?1, R?2, R?3, R7? and R8? are selected form hydrogen, a protected C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group; R4, R?4 are selected from a hydrogen, a hydroxyl, a protected hydroxyl group, a protected C1-C3 hydroxyalkyl group, a C1-C3 alkyl group; n is an integer between 0 and 4; R5, R?5 are selected from a hydrogen, a protecting group comprising C1-C30 aliphatic radicals, C3-C30 cycloaliphatic radicals, C2-C30 aromatic radicals, m is an integer between 1 and 10; at least one of R7 and R?7 is acidic groups or protected acidic groups; Y comprises a protein or peptide moiety, a particle, a micelle, a liposome, an organic molecule, oligomer, polymer or a hydrophilic moiety.
    Type: Application
    Filed: September 26, 2012
    Publication date: March 27, 2014
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Brian James Grimmond, Michael James Rishel, Jeannette Christine Roberts
  • Publication number: 20140044647
    Abstract: The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: Aeon Medix Inc.
    Inventors: Yong Song GHO, Yoon Keun Kim, Su Chul Jang, Oh Youn Kim, Dong-Sic Choi, Yae Jin Yoon
  • Patent number: 8636977
    Abstract: The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: January 28, 2014
    Assignee: Bracco Imaging S.p.A.
    Inventors: Luciano Lattuada, Pierfrancesco Morosini, Fulvio Uggeri, Silvio Aime, Enzo Terreno, Daniela Delli Castelli, Carlo Scolastico, Leonardo Manzoni, Daniela Arosio
  • Patent number: 8637028
    Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: January 28, 2014
    Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology, The Brigham and Women's Hospital
    Inventors: Frank Alexis, Matteo Iannacone, Jinjun Shi, Pamela Basto, Elliott Ashley Moseman, Ulrich von Andrian, Robert S. Langer, Omid C. Farokhzad, Elena Tonti
  • Patent number: 8617514
    Abstract: The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as well as methods of imaging various tissues. The liposome complexes are useful for encapsulation of imaging agents, for example, for use in magnetic resonance imaging. The specificity of the delivery system is derived from the targeting antibodies or antibody fragments.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: December 31, 2013
    Assignee: Georgetown University
    Inventors: Esther H. Chang, Kathleen F. Pirollo
  • Patent number: 8535712
    Abstract: The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposomal delivery system, comprising a stable liposome-forming lipid and a polymerizable colipid, a fraction of which polymerizable colipid polymerizes upon exposure to ionizing radiation, thereby destabilizing the liposomal membrane. Destabilization of liposomes allows for leakage of liposomal contents. The present invention further contemplates methods of diagnosing and treating conditions and diseases that are responsive to liposome-encapsulated or associated agents.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: September 17, 2013
    Assignees: Varian Medical Systems, Inc., Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: David F. O'Brien, Kathy A. McGovern, Bruce Bondurant, Robert Sutherland
  • Publication number: 20130230457
    Abstract: The present invention relates to a formulation of thermosensitive liposomes, and more specifically to a formulation of liposomes comprising phospholipids and a surface active agent, wherein the liposomes support long term storage at temperatures less than or equal to about 8° C., control degradate formation to maximize product potency and release their contents at mild hyperthermic temperatures. Methods of making formulations are also described.
    Type: Application
    Filed: February 15, 2013
    Publication date: September 5, 2013
    Applicant: CELSION CORPORATION
    Inventors: Robert A. REED, Daishui SU
  • Publication number: 20130183234
    Abstract: Compositions useful for target detection, imaging and treatment, as well as methods of production and use thereof, are disclosed herein.
    Type: Application
    Filed: September 26, 2011
    Publication date: July 18, 2013
    Applicants: SIEMENS HEALTHCARE DIAGNOSTICS INC, SIEMENS MEDICAL SOLUTIONS USA INC
    Inventors: Les Oppenheimer, Ismayil M. Guracar
  • Publication number: 20130142729
    Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.
    Type: Application
    Filed: January 3, 2013
    Publication date: June 6, 2013
    Applicants: IMMUNOMEDICS, INC., THE OHIO STATE UNIVERSITY
    Inventors: The Ohio State University, Immunomedics, Inc.
  • Publication number: 20130129636
    Abstract: The present invention provides novel liposomes comprising Gd.DOTA.DSA (gadolinium(III)2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N?-amido-methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-acetic acid), characterised in that said liposome further comprises a neutral, fully saturated phospholipid component (e.g. DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine]), which are of particular use in the preparation of magnetic resonance contrast agents for enhancing a magnetic resonance image of tumours in a mammal.
    Type: Application
    Filed: November 19, 2010
    Publication date: May 23, 2013
    Applicants: IMPERIAL INNOVATIONS LIMITED, MEDICAL RESEARCH COUNCIL
    Inventors: Nazila Kamaly, Tammy Louise Kalber, Gavin David Kenny, Maya Thanou, Andrew David Miller, Jimmy Bell
  • Patent number: 8440167
    Abstract: The present invention provides multiple modalities for detecting LOX-1. More particularly, an imaging composition is provided that allows for the in vivo imaging of atherosclerotic plaque.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: May 14, 2013
    Assignee: University of Virginia Patent Foundation
    Inventors: George A. Beller, David K. Glover, Alexander L. Klibanov, Craig H. Meyer, Dayuan Li, Amit Patel, Christopher M. Kramer
  • Patent number: 8361494
    Abstract: An engineered lipoprotein including (a) a core particle or a plurality of core particles, each core particle has (i) an inner part comprising a hydrophilic active agent and a hydrophilic portion of an amphiphilic cholesterol and (ii) an outer part including a hydrophobic portion of the amphiphilic cholesterol, (b) a layer surrounding the core particle or a plurality of core particles, the layer includes a phospholipid, (c) an apoprotein associated with the layer, and optionally, (d) a homing molecule associated with at least one of the apoprotein or the phospholipid.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: January 29, 2013
    Assignee: The Trustees Of The University of Pennsylvania
    Inventors: I-Wei Chen, Hoon Choi
  • Publication number: 20130011339
    Abstract: Bilayer-nanoparticle compositions comprising a nanoparticle core and a lipid bilayer disposed around the exterior surface of the nanoparticle core are provided. In some embodiments, these bilayer-nanoparticle compositions may be dispersed in an aqueous solution. Associated methods are also provided.
    Type: Application
    Filed: January 9, 2012
    Publication date: January 10, 2013
    Inventors: Vicki Colvin, Arjun Prakash, Huiguang Zhu
  • Patent number: 8349293
    Abstract: The invention relates to the use of metal nanoparticles for the preparation of a composition for diagnosing Alzheimer's disease by MRI.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: January 8, 2013
    Assignee: Guerbet
    Inventor: Claire Corot
  • Publication number: 20120141381
    Abstract: The invention comprises compositions and methods for loading both magnetic resonance contrast agents and therapeutic agents into liposomes, such as low temperature sensitive liposomes (LTSLs). In certain embodiments, a passive technique is used to load the liposomes. In other embodiments, an active technique is used to load the liposomes. In further embodiments, a magnetic resonance contrast agent and Doxorubicin are loaded into the liposomes. The liposome compositions have higher contrast-agent loadings and are more stable, than those known in the art.
    Type: Application
    Filed: February 23, 2010
    Publication date: June 7, 2012
    Applicant: Duke University Office of Technology & Venture
    Inventors: Mark W. Dewhirst, Pavel Yarmolenko, Bradford J. Wood, Matthrew R. Dreher, Ayele H. Negussie
  • Publication number: 20120100079
    Abstract: The present invention relates to a composition comprising a shell structure forming a cavity, wherein said shell structure comprises a drug and wherein said composition is associated with at least one contrast agent; wherein said shell structure is capable of releasing its contents into the exterior upon the application of an external stimulus and wherein said contrast agent comprises magnetic particles which are capable of being detected by Magnetic Particle Imaging (MPI), wherein at least more than 5% (w/w) of the magnetic particles comprised in said contrast agent have a magnetic moment of at least ?18 m 2 A, 10 wherein said magnetic particles are preferably composed of Fe, Co, Ni, Zn or Mn or alloys thereof or oxides of any of these.
    Type: Application
    Filed: June 25, 2010
    Publication date: April 26, 2012
    Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.
    Inventors: Dirk Burdinski, Jeroen A. Pikkemaat, Bertrand Schmitt, Holger Gruell, Sander Langereis
  • Publication number: 20110286937
    Abstract: The present invention provides a glycolipid-containing liposome. In such a glycolipid-containing liposome, the glycolipid includes a plant ceramide portion and a sugar chain portion. The present invention also provides a method of producing a glycolipid-containing liposome. This method includes the following steps of: A) providing a glycolipid in which the glycolipid includes a plant ceramide portion and a sugar chain portion; and B) mixing the provided glycolipid with a liposome raw material and subjecting the mixture to conditions in which a liposome is formed.
    Type: Application
    Filed: February 18, 2009
    Publication date: November 24, 2011
    Applicants: GIFU UNIVERSITY, KATAYAMA CHEMICAL INDUSTRIES CO., LTD.
    Inventors: Makoto Kiso, Hideharu Ishida, Taiji Yamashita, Koichi Igarashi, Masahiko Hirai
  • Publication number: 20110274625
    Abstract: Convection-enhanced delivery (CED) is used as a method to deliver a direct infusion of therapeutic agents to the central nervous centre thus circumventing the blood-blood barrier. A non-PEGylated liposomal composition comprising at least one saturated neutral phospholipid and at least one saturated anionic phospholipid and a therapeutic or diagnostic agent encapsulated therein is used to overcome toxicity associated with high peak drug concentration delivered locally CED as well as to increase tissue distribution volume for an improved sustained drug release.
    Type: Application
    Filed: November 23, 2009
    Publication date: November 10, 2011
    Applicant: MedGenesis Therapeutix ,Inc.
    Inventors: Thomas Redelmeier, Matthias Luz
  • Patent number: 7998462
    Abstract: An improved linker which lacks chiral centers between a hydrophobic anchor for coupling to lipid-based particles and a targeting agent has suitable hydrophobic/hydrophilic properties for use in vivo.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: August 16, 2011
    Assignee: Kereos, Inc.
    Inventor: William D. McGhee
  • Patent number: 7906121
    Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: March 15, 2011
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Publication number: 20100254913
    Abstract: In magnetic resonance imaging (MRI) based on chemical exchange-dependent saturation transfer (CEST), a novel carrier for CEST contrast agents is provided. The carrier is non-spherical and comprises a semipermeable shell, wherein the shell comprises a paramagnetic compound. The shell encloses a cavitycomprising an MR analyte, wherein the semipermeable shell allows diffusion of the MR analyte. The CEST effect is based on the 5 bulk magnetic susceptibility effect caused by the anisotropy of the carrier. This leads to a versatile carrier that does not require interaction of the analyte with a paramgnetic chemical shift reagent.
    Type: Application
    Filed: November 21, 2008
    Publication date: October 7, 2010
    Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.
    Inventors: Dirk Burdinski, Sander Langereis, Jeroen Alphons Pikkemaat
  • Patent number: 7769423
    Abstract: Methods and compositions useful for detecting an in vivo blood pool, monitoring the distribution of a compound of interest to a desired site in an organism by magnetic resonance imaging, monitoring the accumulation of a compound of interest at a desired site in vivo by magnetic resonance imaging, and monitoring the release of liposomal contents to an external stimulus at a desired site in vivo by magnetic resonance imaging are disclosed. Some compositions comprise envirosensitive or non-sensitive liposomes. Contrast agents, such as manganese-based compounds, are also disclosed.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: August 3, 2010
    Assignee: Duke University
    Inventors: Benjamin L. Viglianti, Mark W. Dewhirst, Ana M. Ponce
  • Publication number: 20100158817
    Abstract: The current invention discloses a drug delivery system allowing monitoring of spatial position and drug release, as well as methods and uses thereof. More particularly, the drug delivery system comprises drug carrying particles comprising an internal and external distribution of magnetic resonance imaging contrast agents.
    Type: Application
    Filed: September 21, 2007
    Publication date: June 24, 2010
    Inventors: Sigrid L. Fossheim, Esben A, Nilssen
  • Patent number: 7722855
    Abstract: The invention relates to membrane vesicles from non-pathogenic amoeba, in particular from the amoeba Dictyostelium discoideum, containing a molecule of therapeutic interest, to a method of preparing such vesicles and to the use of said vesicles as a vehicle for transferring the molecule therapeutic interest to an eukaryotic mammalian cell.
    Type: Grant
    Filed: July 13, 2004
    Date of Patent: May 25, 2010
    Assignee: Universite Pierre et Marie Curie-Paris VI
    Inventors: Irène Tatischeff, Annette Alfsen, Françoise Lavialle
  • Patent number: 7718190
    Abstract: Certain diacylglycerol-polyethyleneglycol (DAG-PEG) lipids are especially useful for forming thermodynamically stable liposomes. Such liposomes are useful for a variety of purposes, including the delivery of therapeutic agents.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: May 18, 2010
    Inventors: Brian Charles Keller, Danilo Lasic, Alenka Lasic, legal representative
  • Publication number: 20100111876
    Abstract: The invention relates to the use of metal nanoparticles for the preparation of a composition for diagnosing Alzheimer's disease by MRI.
    Type: Application
    Filed: March 21, 2008
    Publication date: May 6, 2010
    Applicant: Guerbet
    Inventor: Claire Corot
  • Publication number: 20100061938
    Abstract: The current invention discloses a drug delivery system allowing monitoring of spatial position and drug release, as well as methods and uses thereof. More particularly, the drug delivery system comprises drug carrying particles comprising novel combinations of magnetic resonance imaging contrast agents.
    Type: Application
    Filed: September 11, 2007
    Publication date: March 11, 2010
    Applicant: EPITARGET AS
    Inventors: Sigrid L. Fossheim, Esben A. Nilssen
  • Patent number: 7672704
    Abstract: Methods and compositions useful for detecting an in vivo blood pool, monitoring the distribution of a compound of interest to a desired site in an organism by magnetic resonance imaging, monitoring the accumulation of a compound of interest at a desired site in vivo by magnetic resonance imaging, and monitoring the release of liposomal contents to an external stimulus at a desired site in vivo by magnetic resonance imaging are disclosed. Some compositions comprise envirosensitive or non-sensitive liposomes. Contrast agents, such as manganese-based compounds, are also disclosed.
    Type: Grant
    Filed: September 11, 2003
    Date of Patent: March 2, 2010
    Assignee: Duke University
    Inventors: Benjamin L. Viglianti, Mark W. Dewhirst, James R. MacFall, Zeljko Vujaskovic
  • Publication number: 20090311194
    Abstract: Methods and compositions for using magnetosomes as cellular contrast agents and markers for magnetic resonance imaging are provided. Certain methods involve synthesizing magnetosomes in a cell as directed by a nucleotide construct comprising an exogenous polynucleotide sequence, wherein the magnetosome serves as a contrast agent or marker for magnetic resonance imaging. Methods of synthesizing and isolating magnetosomes for introduction into immune-matched cells within a tissue or subject for use as a contrast agent or marker for magnetic resonance imaging are also provided. Also provided are methods for stably transfecting cells to express a polypeptide that drives or modulates magnetosome production in the cell, cells produced by such methods and methods for their isolation, transgenic animals comprising at least one eukaryotic cell produced by such methods, and vectors and delivery systems for the transfection of such cells.
    Type: Application
    Filed: April 28, 2006
    Publication date: December 17, 2009
    Applicants: Emory University, Georgia Tech Research Corporation
    Inventors: Xiaoping Philip Hu, Anthony Wing Sang Chan, Omar Zurkiya
  • Patent number: 7618624
    Abstract: A method for regulating the body weight of an animal by feeding it a liposome-encapsulated antibody against lipase.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: November 17, 2009
    Assignees: Anitox Corporation
    Inventor: Julio Pimentel
  • Publication number: 20090274630
    Abstract: Red blood cell-derived vesicles (RDV) as a nanoparticle drug delivery system. The RDV are smaller than one micrometer, capable of encapsulating and delivering an exogenous substance into cells. The substance may be at least one selected from the group consisting of fluorophores, nucleic acids, superparamagnetic compounds and therapeutic agents. The RDV are capable of delivering encapsulated substances into cells including stem cells. The delivered substance within the cell or stem cell may be traced or tracked using a suitable device either in vitro or in vivo.
    Type: Application
    Filed: March 16, 2009
    Publication date: November 5, 2009
    Applicant: National Health Research Institutes
    Inventor: Dong-Ming HUANG
  • Publication number: 20090214441
    Abstract: The invention relates to chelate compounds which can be used in MRI, the chelates being intended to be conveyed by lipophilic transporters, such as lipid nanoparticles or liposomes. The invention also relates to compounds comprising, in association, these chelates and these transporters, if appropriate connected via chemical bonding groups, and to their use in diagnostic imaging, it being possible for this association additionally to comprise biological targeting markers, denoted biovectors.
    Type: Application
    Filed: March 24, 2006
    Publication date: August 27, 2009
    Applicant: GUERBET
    Inventor: Marc Port
  • Publication number: 20090191131
    Abstract: The present invention relates to a method of imaging of an animate human or non-human animal body, which method comprises: administering parenterally to said body a particulate material comprising a matrix or membrane material and at least one contrast generating species, which matrix or membrane material is responsive to a pre-selected physiological parameter whereby to alter the contrast efficacy of said species in response to a change in the value of said parameter; generating image data of at least part of said body in which said species is present; and generating therefrom a signal indicative of the value or variation of said parameter in said part of said body. The invention also relates to contrast media for imaging a physiological parameter.
    Type: Application
    Filed: January 15, 2009
    Publication date: July 30, 2009
    Inventors: Sigrid Lise Fossheim, Jo Klaveness, Atle Bjornerud, Pal Rongved, Klaes Golman, Roald Skurtveit
  • Patent number: 7560097
    Abstract: A pharmaceutical preparation containing magnetic vesicular particles is disclosed, wherein the magnetic vesicular particles each include magnetic microparticles within a lipid membrane, an organic compound having at least two groups selected from the group consisting of a hydroxyl group, a carboxyl group, a carbamoyl group, an amino group, a mercapto group, a sulfo group, a dithio group, a thiocarboxyl group and a dithiocarboxyl group is bonded to the magnetic microparticle, and the magnetic vesicular particles satisfy the following equation: 0.05?R/(r×100)?1.5 wherein R represents an average grain size of the magnetic vesicular particles and r represents an average particle size of magnetic microparticles included in the magnetic vesicular particles.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: July 14, 2009
    Assignee: Konica Minolta Medical & Graphic, Inc.
    Inventor: Toshihisa Takeyama
  • Publication number: 20090142273
    Abstract: A chemical exchange saturation transfer (CEST) contrast agent is provided. One embodiment includes a ligand and a functional group linked to the ligand. The functional group has a hydrogen exchange site and is capable of undergoing a change in chemical functionality by enzyme catalysis or reaction with a metabolite to change the chemical exchange rate or the MR frequency of the hydrogen exchange site.
    Type: Application
    Filed: June 8, 2007
    Publication date: June 4, 2009
    Inventors: Mark Pagel, Byunghee Yoo, Guanshu Liu, Rachel Rosenblum
  • Patent number: RE45195
    Abstract: Example compositions of liposomes with hydrophilic polymers on their surface, and containing relatively high concentrations of contrast-enhancing agents for computed tomography are provided. Example pharmaceutical compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making the liposomes containing high concentrations of contrast-enhancing agents, and example methods for using the compositions.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: October 14, 2014
    Assignees: Marval Pharma, Inc., Case Western Reserve University, Cleveland State University
    Inventors: Ananth Annapragada, Ravi V. Bellamkonda, Eric Hoffman, Chandra Vijayalakshmi, Chen-Yu Kao